Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTCQB:OTLC) has formed a joint venture with Golden Mountain Partners to accelerate the clinical development of its pharmaceutical pipeline. An initial investment of $1.5 million from GMP aims to enhance commercialization efforts. This partnership builds on a relationship that began in 2020, focusing on therapies for oncology and COVID-19. Oncotelic plans to pursue an initial public offering (IPO), looking to replicate recent successes in TGF-β asset IPOs. The CEO expresses optimism for swift advancements in treatment availability.
Oncotelic Therapeutics (OTCQB:OTLC) has announced the discontinuation of enrollment in its OT-101 clinical trial for COVID-19 patients, having randomized 32 out of the planned 36 patients. This decision was motivated by the rise of severe COVID-19 variants in Latin America, which strained medical infrastructure. The trial aimed to assess the role of TGF-beta in COVID-19 and expected to provide significant biomarker data. The company's lead drug, OT-101, targets TGF-β linked to COVID-19 symptoms and is the only therapeutic of its kind currently being evaluated.
Oncotelic Therapeutics (OTCQB:OTLC) is collaborating with the Chopra Foundation and Heart Care Foundation to provide COVID-19 relief in India, supplying medicines including PulmoHeal™, which aids respiratory recovery. PulmoHeal™ is available OTC and is designed to address unmet medical needs amidst a surge of over 400,000 daily cases in India. The initiative aims to gather data on various COVID-19 treatments through a Post Marketing Survey platform. This humanitarian effort combines PulmoHeal™ with oxygen support, enhancing immediate and long-term recovery for affected patients.
Oncotelic Therapeutics (OTLC) announced positive results from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal™ in India. The trial demonstrated no adverse events requiring treatment discontinuation, with 91% of patients achieving improved conditions. Key findings include normalized vital signs and significant improvements in oxygen saturation and respiratory rates by day 28. PulmoHeal™, developed in partnership with Windlas Biotech, has potential for broad-spectrum antiviral efficacy, confirmed against multiple SARS-CoV-2 variants.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced a presentation at AACR-2021 discussing a combination therapy using Trabedersen, an anti-sense oligonucleotide targeting TGF-β2, and Proleukin (IL-2) for treating solid cancers. This approach aims to enhance immune response while mitigating IL-2 toxicity. In vitro studies showed reduced cancer cell viability and significant tumor growth delay in humanized mouse models. Oncotelic also received regulatory approval for a phase 1b trial of the OT-101/IL-2 combination, further supporting its innovative cancer treatment pipeline.
Oncotelic Therapeutics (OTCQB:OTLC) announced a collaboration with the Chopra Foundation and Jiva to host a webinar titled Ayurvedic Perspectives on COVID-19 on April 15, 2021. The event will feature experts discussing various aspects of COVID-19 management, including inflammation and Ayurvedic approaches. Notably, Oncotelic's PulmoHeal includes a mobile app for monitoring respiratory health and a lung therapy supplement that has demonstrated efficacy against COVID-19. The company continues to focus on leveraging AI for health assessments amid the ongoing pandemic.
Oncotelic Therapeutics (OTCQB:OTLC), formerly known as Mateon Therapeutics, announced on March 30, 2021, that the Financial Industry Regulatory Authority (FINRA) has approved its name and ticker symbol change. The new ticker symbol, effective immediately, is OTLC, replacing MATN. This follows a corporate action approved by shareholders in August 2020, which included the name change finalized in November 2020. Oncotelic focuses on developing RNA therapeutics and small molecule drugs targeting cancer and infectious diseases, particularly emphasizing rare pediatric cancers.